pathway-based drug repositioning for breast cancer molecular subtypes
Clicks: 227
ID: 146706
2018
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
72.5
/100
227 views
181 readers
Trending
AI Quality Assessment
Not analyzed
Breast cancer is a major public health problem which treatment needs new pharmacological options. In the last decades, during the postgenomic era new theoretical and technological tools that give us novel and promising ways to address these problems have emerged. In this work, we integrate several tools that exploit disease-specific experimental transcriptomic results in addition to information from biological and pharmacological data bases obtaining a contextual prioritization of pathways and drugs in breast cancer subtypes. The usefulness of these results should be evaluated in terms of drug repurposing in each breast cancer molecular subtype therapy. In favor of breast cancer patients, this methodology could be further developed to provide personalized treatment schemes. The latter are particularly needed in those breast cancer subtypes with limited therapeutic options or those who have developed resistance to the current pharmacological schemes.
| Reference Key |
meja-pedroza2018frontierspathway-based
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Raúl A. Mejía-Pedroza;Jesús Espinal-Enríquez;Jesús Espinal-Enríquez;Enrique Hernández-Lemus;Enrique Hernández-Lemus |
| Journal | chemical research in chinese universities |
| Year | 2018 |
| DOI | 10.3389/fphar.2018.00905 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.